

Market Announcement

5 June 2026

Microba Life Sciences Limited (ASX: MAP) – Suspension from Quotation

The securities of Microba Life Sciences Limited ('MAP') will be suspended from quotation immediately under Listing Rule 17.2 at the request of MAP, pending the release of an announcement by MAP.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in MAP's request for voluntary suspension; or
- the release of the announcement to the market.

MAP's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Compliance

Ms Renee Hutchens
Adviser, ASX Listings Compliance (Sydney)
20 Bridge Street,
SYDNEY, NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for Voluntary Suspension – Microba Life Sciences Ltd (ASX: MAP)

Microba Life Sciences Ltd (ASX: MAP) (**Microba**), requests a voluntary suspension of all its quoted securities to apply from the commencement of trading on Friday, 5 June 2026.

The voluntary suspension is requested in relation to a material capital raise (**Capital Raise**) and update on Microba's path to break even (**Break Even Update**) as referenced in the trading halt request on 3 June 2026. In accordance with ASX Listing Rule 17.2, Microba provides the following information:

- (a) At its request, Microba entered a trading halt on 3 June 2026, pending an announcement regarding an update to a path to break even plan and a Capital Raise, and to allow these matters to be progressed and completed in an orderly manner;
- (b) Microba requires additional time to finalise the Capital Raise. Microba now expects to conclude these matters and to announce both the Capital Raise and the Break Even Update on Thursday, 11 June 2026 (noting that Monday, 8 June 2026 is public holiday and a non-trading day on the ASX), and accordingly requests that the voluntary suspension apply through to that date;
- (c) Microba considers that continued trading in its securities ahead of that announcement would risk the market trading on an uninformed basis and without the benefit of an update to the path to break even plan, and could materially prejudice the orderly completion of the Capital Raise. The voluntary suspension is therefore requested to preserve a fair and informed market and to support the best available outcome for shareholders;
- (d) Microba requests the voluntary suspension be put in place until the earlier of commencement of trading on Thursday, 11 June 2026 or such time that Microba makes an announcement to the market in relation to the Capital Raise and Break Even Update;
- (e) Microba is not aware of any reason why the voluntary suspension should not be granted; and
- (f) Microba is not aware of any other information necessary to inform the market about the voluntary suspension.

Yours sincerely,

James Heath

CFO & Company Secretary

This announcement has been authorised for release by the Board of Directors.

For further information, please contact:



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations

investor@microba.com
<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com

For personal use only



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621